Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.41 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | RARB | P10826 | 3/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489090 | 0.91 | PPARG (0.43) | PPARGDCTPP1 | |
| SCHEMBL6490173 | 0.90 | RARB (0.47) | PPARGTP53TSHRPLA2G4BDCTPP1 | |
| SCHEMBL6497678 | 0.89 | PTPN11 (0.46) | PPARGPLA2G4BPTPN11 | |
| SCHEMBL6488344 | 0.87 | MCL1 (0.47) | PPARGPLA2G2APLA2G4BMCL1 | |
| SCHEMBL6500130 | 0.87 | DCTPP1 (0.47) | PPARGDCTPP1MCL1 | |
| SCHEMBL6301607 | 0.87 | PPARG (0.58) | PPARGTP53TSHRPLA2G4BRARB | |
| SCHEMBL6500949 | 0.87 | BCL2 (0.54) | PLA2G2ATP53PLA2G4BMCL1 | |
| SCHEMBL6488196 | 0.87 | PPARG (0.39) | PPARGTP53DCTPP1 | |
| SCHEMBL6308005 | 0.86 | PPARG (0.57) | PPARGTP53TSHRPLA2G4BRARB | |
| SCHEMBL6303646 | 0.86 | PPARG (0.57) | PPARGTP53TSHRPLA2G4BRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PPARG 233/4885PLA2G2A 4801/4885TP53 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.